A Proof-of-concept Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of 4SC-201 and the Treatment Combination of Sorafenib Plus 4SC-201 in Patients With Hepatocellular Carcinoma Exhibiting Progressive Disease Under Sorafenib Treatment.
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2016
At a glance
- Drugs Resminostat (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms SHELTER
- Sponsors 4SC
- 02 Dec 2016 Results of biomarker analysis from SHELTER,SAPHIRE and SHORE trials presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
- 10 Nov 2016 According to a 4SC media release, full data set of this trial will be presented at an upcoming scientific conference.
- 06 May 2014 Results published in an 4SC media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History